Project Grant R01HL171971
Award Date
8/15/24
Completion Date
7/31/29
Dollars Obligated
$685K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award of $540,856 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to understand the gene regulatory networks that control endocardial-specific gene expression. The key objectives are to: 1) Identify transcriptional regulators of endocardial-restricted gene expression, 2) Determine how valve-restricted gene expression is achieved, and 3) Define the regulation and function of the SLC16A2 gene during heart injury...
This Project Grant award of $734,607 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to elucidate the key endothelial mechanisms that direct hematopoietic stem cells (HSCs) across the blood vessel wall and into their niche. The research, conducted by Boston Medical Center Corporation, will use high-resolution live cell imaging, structure-function studies, and in vivo proximity-dependent biotinylation in zebrafish to define the endothelial...
This Project Grant award of $726,408 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will fund research to define the role of endothelial TFEB in mitigating cardiovascular toxicity induced by cancer therapies. The award recipient, the University of Cincinnati, will leverage its expertise in endothelial cell biology and transgenic mouse models to explore how modulating the TFEB pathway can protect against...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $112,034 to the Rector & Visitors of the University of Virginia (UVA) to support research on the mechanisms controlling arterial-venous specification during embryonic vascular development. The key objectives are to: Rigorously define the cell cycle state of arterial and venous endothelial cells in the developing embryo using FUCCI2...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA Program 93.837 Cardiovascular Diseases Research) provides $740,037 to the University of California, Los Angeles (UCLA) to investigate the role of cardiac fibroblasts in regulating angiogenesis following myocardial infarction. The key objectives are to evaluate the function of anti-angiogenic factors, such as collagen type XVIII, and determine if the expression of pro-angiogenic factors, such as slit guidance ligand...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $684,814 to The Regents of the University of California, San Francisco to conduct research on the suppression of alveolar stem cells by tissue-resident lymphocytes in emphysema. The primary objectives are to investigate how lung stromal factors modify the inflammatory response to viral infections and tobacco smoke, and how this leads to the suppression of alveolar...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $788,513 to the University of California, San Diego to study the mechanisms underlying maintenance of cardiac chamber identity in zebrafish. The research aims to elucidate the downstream effectors of FGF-MEK-ERK signaling that regulate ventricular cardiomyocyte identity, identify factors conferring differential plasticity within distinct ventricular regions, and...
The University of California, Davis received a $400,417 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to conduct research on cardiac regenerative therapy using gene-edited stem cells. The goal is to improve transplantation outcomes and address the critical role of inflammation-induced cell death that impedes current cardiac stem cell therapies. The research aims to develop new treatments for end-stage heart failure, a...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) will provide $706,220 to the University of Illinois to conduct research on the role of nuclear pore components in vascular function. The key focus is investigating how phosphorylation of the nucleoporin NUP93 regulates the subcellular localization of the transcriptional regulator YAP, and the impact on endothelial inflammation and atherosclerosis. The research plan...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $528,179 to the University of Miami to investigate reprogramming of bone marrow-derived monocytes as a novel strategy to improve neovascularization and outcomes in peripheral arterial disease and critical limb ischemia. The key objectives are to: 1) determine if extracellular vesicles mediate the systemic effect of ischemia training on monocyte reprogramming; 2)...